Data Insights

Bintrafusp alfa by Merck for Nasopharyngeal Cancer: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Nasopharyngeal Cancer

Data Insights

Bintrafusp alfa by Merck for Non-Small Cell Lung Cancer: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase III for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Non-Small Cell Lung Cancer

Data Insights

Bintrafusp alfa by Merck for Gallbladder Cancer: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase III for Gallbladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Gallbladder Cancer

Data Insights

Bintrafusp alfa by Merck for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Bintrafusp alfa by Merck for Ureter Cancer: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase I for Ureter Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Ureter Cancer

Data Insights

Bintrafusp alfa by Merck for Urethral Cancer: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase I for Urethral Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Urethral Cancer

Data Insights

Bintrafusp alfa by Merck for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Kidney Cancer (Renal Cell Cancer)

Data Insights

Bintrafusp alfa by Merck for Small-Cell Lung Cancer: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Small-Cell Lung Cancer

Data Insights

Bintrafusp alfa by Merck for Gastric Cancer: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Gastric Cancer

Data Insights

Bintrafusp alfa by Merck for Melanoma: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase II for Melanoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Melanoma

Data Insights

Bintrafusp alfa by Merck for Urinary Tract Cancer: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase I for Urinary Tract Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Urinary Tract Cancer

Data Insights

Bintrafusp alfa by Merck for Bladder Cancer: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase I for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Bladder Cancer

Data Insights

Bintrafusp alfa by Merck for Metastatic Colorectal Cancer: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Metastatic Colorectal Cancer

Data Insights

Bintrafusp alfa by Merck for Soft Tissue Sarcoma: Likelihood of Approval

Bintrafusp alfa is under clinical development by Merck and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Bintrafusp Alfa in Soft Tissue Sarcoma